Agentix Corp
Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. It develops AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, … Read more
Agentix Corp (AGTX) - Net Assets
Latest net assets as of December 2025: $-3.50 Million USD
Based on the latest financial reports, Agentix Corp (AGTX) has net assets worth $-3.50 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.40K) and total liabilities ($3.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.50 Million |
| % of Total Assets | -54690.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -30680.72% |
| Growth Volatility | 466.82 |
Agentix Corp - Net Assets Trend (2013–2025)
This chart illustrates how Agentix Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Agentix Corp (2013–2025)
The table below shows the annual net assets of Agentix Corp from 2013 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $-3.10 Million | -21.25% |
| 2024-03-31 | $-2.56 Million | -13.83% |
| 2023-03-31 | $-2.25 Million | -1106.51% |
| 2022-03-31 | $223.46K | +277.65% |
| 2021-03-31 | $-125.78K | 0.00% |
| 2020-03-31 | $-125.78K | -136.74% |
| 2019-03-31 | $-53.13K | +18.36% |
| 2018-03-31 | $-65.08K | -741.51% |
| 2017-03-31 | $10.14K | -0.06% |
| 2016-03-31 | $10.15K | -91.54% |
| 2014-03-31 | $119.98K | +71.40% |
| 2013-03-31 | $70.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Agentix Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 647152800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $40.07K | % |
| Other Comprehensive Income | $88.92K | % |
| Other Components | $3.29 Million | % |
| Total Equity | $-3.10 Million | 100.00% |
Agentix Corp Competitors by Market Cap
The table below lists competitors of Agentix Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gossan Resources Ltd
V:GSS
|
$1.57 Million |
|
Dalrada Financial Corp
PINK:DFCO
|
$1.57 Million |
|
Panbela Therapeutics Inc
NASDAQ:PBLA
|
$1.57 Million |
|
Instituto Rosenbusch S.A.
BA:ROSE
|
$1.57 Million |
|
Intra Energy Corporation
AU:IEC
|
$1.57 Million |
|
WarpSpeed Taxi Inc
PINK:WRPT
|
$1.56 Million |
|
Melar Acquisition Corp. I Warrant
NASDAQ:MACIW
|
$1.56 Million |
|
CURAA
NSE:CURAA
|
$1.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Agentix Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -2,560,222 to -3,104,249, a change of -544,027.
- Net loss of 567,048 reduced equity.
- Other comprehensive income increased equity by 88,916.
- Other factors decreased equity by 65,895.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-567.05K | -18.27% |
| Other Comprehensive Income | $88.92K | +2.86% |
| Other Changes | $-65.89K | -2.12% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Agentix Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-03-31 | $8.00 | $0.05 | x |
| 2014-03-31 | $21.85 | $0.05 | x |
| 2016-03-31 | $1.70 | $0.05 | x |
| 2017-03-31 | $1.69 | $0.05 | x |
| 2018-03-31 | $-10.82 | $0.05 | x |
| 2019-03-31 | $-4.81 | $0.05 | x |
| 2020-03-31 | $-0.06 | $0.05 | x |
| 2021-03-31 | $-0.04 | $0.05 | x |
| 2022-03-31 | $0.07 | $0.05 | x |
| 2023-03-31 | $-0.06 | $0.05 | x |
| 2024-03-31 | $-0.06 | $0.05 | x |
| 2025-03-31 | $-0.08 | $0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Agentix Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-458.94%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -62.50% | 0.00% | 0.00x | 1.00x | $-58.00K |
| 2014 | -174.10% | 0.00% | 0.00x | 1.16x | $-220.88K |
| 2016 | -1725.21% | -617.18% | 1.62x | 1.73x | $-176.14K |
| 2017 | -2945.71% | -692.68% | 3.92x | 1.09x | $-299.86K |
| 2018 | 0.00% | -18438.71% | 0.32x | 0.00x | $-408.36K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-85.41 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-131.41K |
| 2021 | 0.00% | -30922.02% | 13.33x | 0.00x | $-370.85K |
| 2022 | -599.81% | -108092.50% | 0.00x | 1.31x | $-1.36 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.15 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-329.13K |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-256.62K |
Industry Comparison
This section compares Agentix Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Agentix Corp (AGTX) | $-3.50 Million | -62.50% | N/A | $1.57 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |